January 29, 2015 7:28 AM ET


Company Overview of Tocagen Inc.

Company Overview

Tocagen Inc. is a clinical-stage biopharmaceutical company that engages in the discovery, development, and commercialization of gene therapy products for the selective treatment of cancer. The company focuses on developing a treatment for high grade glioma, a type of brain cancer that includes glioblastoma multiforme and anaplastic astrocytomas. Its products include Toca 511 and Toca FC that allows selective targeting of cancer cells, as well as a selective, local, and systemic antitumor immune response without off-target toxicity; Toca Gamma that leverages the immune system to clear locally injected cancerous tumors, as well as to create an arsenal of targeted immune cells to kill more dist...

3030 Bunker Hill Street

Suite 230

San Diego, CA 92109

United States

Founded in 2007





Key Executives for Tocagen Inc.

Age: 61
Co-Founder and Executive Vice President of Research & Pharmaceutical Development
Age: 66
Age: 63
Chief Financial Officer
Age: 63
Head of Business Development and Product Manager
Compensation as of Fiscal Year 2014.

Tocagen Inc. Key Developments

Tocagen Inc. Appoints Franklin M. Berger to the Board of Directors

Tocagen Inc. announced that Franklin M. Berger has been appointed to the board of directors. Mr. Berger will also serve as the chairman of a newly formed audit committee responsible for overseeing Tocagen's accounting, financial reporting, disclosure and financial risk management activities. He previously served as managing director, equity research, and senior biotechnology analyst at J.P. Morgan Securities from 1998 to 2003. Presently, Mr. Berger serves on the board of directors of Immune Design and Five Prime Therapeutics. He has served on the board of directors for numerous companies, including Seattle Genetics Inc. Mr. Berger is a founder and managing director of FMB Research and previously co-founded the small-cap focused NEMO fund at Sectoral Asset Management.

Tocagen Inc. Appoints Faheem Hasnain as Chairman of the Board of Directors

Tocagen Inc. announced that Faheem Hasnain, president and chief executive officer of Receptos Inc. has been appointed as chairman of the board of directors. Mr. Hasnain is a distinguished industry leader with over 30 years of experience in the biopharmaceutical industry. Presently, he serves as chairman of the board of Sente Inc. Previously, he was chairman of the board of Ambit Biosciences Corporation, acquired by Daiichi Sankyo Company, and he served on the board of directors of Seragon Pharmaceuticals, acquired by Roche; Aragon Pharmaceuticals, acquired by Johnson & Johnson; and Tercica Inc., acquired by Ipsen. Prior to joining Receptos, Mr. Hasnain was the president and chief executive officer and a director of Facet Biotech.

Tocagen Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 10:30 AM

Tocagen Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 10:30 AM. Venue: The Palace Hotel, San Francisco, CA 94105, United States. Speakers: Harry E. Gruber, Co-Founder, Chairman, Chief Executive Officer and President.

Similar Private Companies By Industry

Company Name Region
PathoGene, L.L.C. United States
Alkira Therapeutics, Inc. United States
Novira Therapeutics, Inc. United States
Ambion, Inc. United States
Aphton Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tocagen Inc., please visit www.tocagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.